A detailed history of Ci Investments Inc. transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Ci Investments Inc. holds 4,872 shares of NTLA stock, worth $47,696. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,872
Previous 4,835 0.77%
Holding current value
$47,696
Previous $108,000 7.41%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

BUY
$19.72 - $27.36 $729 - $1,012
37 Added 0.77%
4,872 $100,000
Q2 2024

Aug 12, 2024

BUY
$20.02 - $27.22 $19,959 - $27,138
997 Added 25.98%
4,835 $108,000
Q1 2024

May 13, 2024

BUY
$23.82 - $32.8 $71 - $98
3 Added 0.08%
3,838 $106,000
Q4 2023

Feb 12, 2024

BUY
$23.16 - $32.34 $27,884 - $38,937
1,204 Added 45.76%
3,835 $117,000
Q3 2023

Nov 13, 2023

SELL
$31.62 - $45.78 $2,497 - $3,616
-79 Reduced 2.92%
2,631 $83,000
Q2 2023

Aug 11, 2023

BUY
$34.58 - $46.03 $11,757 - $15,650
340 Added 14.35%
2,710 $111,000
Q1 2023

May 12, 2023

SELL
$33.3 - $44.82 $998 - $1,344
-30 Reduced 1.25%
2,370 $88,000
Q4 2022

Feb 10, 2023

BUY
$33.21 - $62.69 $66,785 - $126,069
2,011 Added 516.97%
2,400 $84,000
Q3 2022

Nov 14, 2022

SELL
$53.92 - $71.7 $1,509 - $2,007
-28 Reduced 6.71%
389 $22,000
Q2 2022

Aug 12, 2022

SELL
$38.49 - $76.21 $5,658 - $11,202
-147 Reduced 26.06%
417 $22,000
Q1 2022

May 12, 2022

BUY
$58.27 - $118.99 $12,061 - $24,630
207 Added 57.98%
564 $41,000
Q4 2021

Feb 11, 2022

BUY
$100.76 - $138.36 $7,053 - $9,685
70 Added 24.39%
357 $42,000
Q3 2021

Nov 12, 2021

BUY
$132.37 - $176.78 $37,990 - $50,735
287 New
287 $39,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $744M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Ci Investments Inc. Portfolio

Follow Ci Investments Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ci Investments Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ci Investments Inc. with notifications on news.